Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue samples from patients with ductal breast carcinoma in situ.
|Breast Cancer||Genetic: RNA analysis Genetic: gene expression analysis Genetic: reverse transcriptase-polymerase chain reaction Other: laboratory biomarker analysis|
|Study Design:||Observational Model: Other
Time Perspective: Retrospective
|Official Title:||A Correlative Science Study for ECOG E5194|
- Ipsilateral local failure (first event of invasive or DCIS recurrence) [ Time Frame: 1 month ]
- Contralateral breast cancer (invasive or DCIS) [ Time Frame: 1 month ]
|Actual Study Start Date:||March 5, 2010|
|Study Completion Date:||April 5, 2010|
|Primary Completion Date:||April 5, 2010 (Final data collection date for primary outcome measure)|
- To validate the prognostic utility of a new ductal breast carcinoma in situ (DCIS) genomic score and the Oncotype DX Recurrence Score® assay in tissue samples from patients with DCIS enrolled on clinical trial ECOG-E5194.
OUTLINE: RNA extracted from archived tissue samples are analyzed for gene expression profile by Oncotype DX Recurrence Score® assay (a reverse transcriptase-PCR-based assay).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01132560
|Principal Investigator:||Lawrence J. Solin, MD, FACR||Abramson Cancer Center of the University of Pennsylvania|